×
About 42,540 results

ALLMedicine™ Non-small Cell Lung Cancer Center

Research & Reviews  14,359 results

Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in p...
https://doi.org/10.1007/s00259-022-05788-8 10.1016/S0140-6736(15)01281-7 10.1016/S1470-2045(19)30407-3 10.1016/j.cllc.2017.10.014 10.1038/s12276-018-0191-1 10.1158/1078-0432.CCR-17-1970 10.1093/annonc/mdv182 10.1093/annonc/mdx286 10.1007/s10637-017-0534-0 10.1136/esmoopen-2017-000278 10.1001/jamaoncol.2017.2925 10.6004/jnccn.2019.0059 10.1093/annonc/mdy275 10.1007/s00259-019-04573-4 10.2967/jnumed.119.233056 10.1186/s13550-019-0473-1 10.1186/s40425-016-0162-9 10.1016/S1470-2045(17)30074-8 10.2967/jnumed.108.057307 10.1093/biomet/81.3.515 10.1016/j.ejca.2018.03.006 10.1038/s41571-019-0218-0 10.1056/NEJMoa1412082 10.1002/acr.23177 10.1016/j.ejca.2020.03.017 10.1016/j.cllc.2018.10.002 10.1634/theoncologist.2017-0384 10.1007/s00432-018-2805-3 10.1016/j.lungcan.2017.11.019 10.3389/fonc.2020.566297 10.1016/j.bpg.2020.101703 10.1016/j.gie.2017.04.033 10.14309/crj.2017.57 10.1136/gutjnl-2019-BSGAbstracts.277 10.1259/bjr.20190832 10.1177/1534735419846379 10.1093/annonc/mdx108 10.1126/science.aan4236 10.3390/microorganisms8111827 10.1016/j.annonc.2020.01.006 10.3892/ol.2019.9899
European Journal of Nuclear Medicine and Molecular Imaging; Humbert O, Bauckneht M et. al.

May 14th, 2022 - We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on 18FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). Data from patients with IIIB/IV NSCLC includ...

Impact of preoperative diagnostic biopsy procedure on spread through air spaces and rel...
https://doi.org/10.1016/j.chest.2022.05.002
Chest Lee GY, Chung JH et. al.

May 14th, 2022 - Spread through air spaces (STAS) is a recently determined pathologic phenomenon of lung cancer with significant prognostic impact. This study aimed to analyze the unexplored correlation between preoperative biopsy procedure and a higher risk of ST...

Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congres...
https://doi.org/10.1080/07357907.2022.2077566
Cancer Investigation; Arora S, Asawa P et. al.

May 14th, 2022 - The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our op...

Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus...
https://doi.org/10.1200/EDBK_358995
American Society of Clinical Oncology Educational Book. A... Provencio M, Calvo V et. al.

May 14th, 2022 - The treatment scenario for patients with resectable non-small cell lung cancer has changed dramatically with the incorporation of immunotherapy. The introduction of immunotherapy into treatment algorithms has yielded improved clinical outcomes in ...

see more →

Guidelines  23 results

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628757
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Definition and assessment of high risk in patients considered for lobectomy for stage I...
https://doi.org/10.1016/j.jtcvs.2021.07.030
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0013
Journal of the National Comprehensive Cancer Network : JN... Ettinger DS, Wood DE et. al.

Mar 6th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targete...

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHES...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177089
Chest Mazzone PJ, Gould MK et. al.

Apr 27th, 2020 - The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendat...

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lun...
https://doi.org/10.2214/AJR.19.21135
AJR. American Journal of Roentgenology; Chen L, Smith DA et. al.

Jul 31st, 2019 - OBJECTIVE. The purpose of this article is to provide an imaging-based guide of the modern genomic classifications and targeted therapies for advanced non-small cell lung cancer (NSCLC) with an emphasis on the relevance of the 2018 American Society...

see more →

Drugs  145 results see all →

Clinicaltrials.gov  1,253 results

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
https://clinicaltrials.gov/ct2/show/NCT02759835

May 13th, 2022 - Background: EGFR tyrosine kinase inhibitors (TKI) have significantly improved the response rate (RR) and survival in patients with tumors harboring EGFR-sensitizing mutations. An invariable consequence of treatment with EGFR-TKIs is the developmen...

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT05372081

May 13th, 2022 - Lung cancer is the primary cause of cancer death worldwide regardless of gender or age group. Based on the most recent statistics for our country, every year about 9000 new cases of lung cancer are diagnosed. Lung cancer is the most common type of...

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations
https://clinicaltrials.gov/ct2/show/NCT05364073

May 13th, 2022 - This is a Phase 1b, open-label, multi-center, dose-escalation and dose-expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic NSCLC with a...

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02133196

May 13th, 2022 - Background: Patients with metastatic non-small cell lung cancer (NSCLC) have few approved therapeutic options and those that exist are of transient benefit. Recent clinical experiences with experimental agents that release checkpoints on the host ...

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02194738

May 13th, 2022 - PRIMARY OBJECTIVES: I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies. II. To obtain clinically annotated tumor tissue and patient-matched non-malignant deox...

see more →

News  1,235 results

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC
https://www.onclive.com/view/sotorasib-shows-impressive-2-year-os-rate-in-kras-g12c-nsclc

May 2nd, 2022 - Sotorasib (Lumakras) demonstrated an overall survival (OS) rate of 32.5% (95% CI, 25.0%-40.2%) at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), according to longer follow-up data from the phase 1/2 CodeBreaK 100 tri...

Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC
https://www.medpagetoday.com/hematologyoncology/lungcancer/98513

May 2nd, 2022 - Patients with unresectable stage III non-small cell lung cancer (NSCLC) had a higher response rate and better progression-free survival when novel targeted agents were added to treatment with durvalumab (Imfinzi), a phase II randomized trial showe...

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC
https://www.onclive.com/view/durvalumab-plus-oleclumab-or-monalizumab-induces-increased-response-rates-in-nsclc

Apr 28th, 2022 - Consolidation therapy with durvalumab (Imfinzi) and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer (NSCLC), according to interim data from the phase 2 COAST stu...

see more →

Patient Education  1 results see all →